Comparison of the response to HBS Ag vaccine in chronic renal failure patients with different GFR levels

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT138803121267N8

Enrollment

300

Registered

2009-08-30

Start date

2007-08-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure. Chronic renal failure

Interventions

Intervention 1: Vaccination with Engrix with dosage of 40 milligramgr, IM in months 0, 1, 6. Intervention 2: Vaccination with Engrix with dosage of 20 milligram, IM in months 0, 1, 6.

Prevention

Vaccination with Engrix with dosage of 40 milligramgr, IM in months 0, 1, 6

Vaccination with Engrix with dosage of 20 milligram, IM in months 0, 1, 6

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Presence of Chronic Renal Failure, age between 18 and 85 yea, negative HBS Ab, Exclusion criteria: Receiving immunosuppressive drug, previous HBV vaccinations

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
HBS Ab. Timepoint: 4-8 weeks after the latest vaccine dose. Method of measurement: lab test.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mitra Mahdavi Mazde

Urology and Nephrology Research Center (UNRC), Shahid Beheshti University, M.C.( SBMU), Tehran, I.R.

Research@unrc.ir+98 21 2256 7222

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026